Society for Clinical Research Sites Adds Oracle as a New Global Impact Partner
Ellicott City, January 26, 2016 – The Society for Clinical Research Sites (SCRS), the global trade organization fully dedicated to representing the interests of clinical research sites, today announced a two-year relationship with Oracle, who provides integrated cloud application, platform services and engineered systems. Oracle will participate as a Global Impact Partner (GIP) and align with 33 other sponsors, CROs, and service providers dedicated to promoting high-level communication and meaningful collaboration between industry stakeholders and clinical research sites globally.
“We are excited to have a company like Oracle included in our Global Impact Partner program. They will bring a unique perspective to the table for both the sites and our other GIPs. Diversifying our GIPs adds bench strength to our organization which makes us stronger,” said Christine Pierre, president of SCRS.
As a Global Impact Partner (GIP), Oracle will participate on the SCRS Global Impact Board at an executive level, and work closely with SCRS’ Leadership Council to determine strategic initiatives for SCRS.
About SCRS
SCRS is a global trade organization founded in 2012 which represents over 2,600 research sites in 42 countries. SCRS’ mission is to unify the voice of the global clinical research site community for greater site sustainability. SCRS has become an active partner in industry-wide initiatives and dialogues focused on improving the clinical research enterprise. Sites and the companies that sponsor or support the work conducted at clinical research sites will benefit from membership and partnership. Visit MySCRS.org.
About Oracle
With more than 420,000 customers-including 100 of the Fortune® 100-and with deployment across a wide variety of industries in more than 145 countries, Oracle offers a comprehensive and fully integrated stack of cloud applications, platform services and engineered systems.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
